[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 677
1. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Radiographic objective responses (partial responses) were observed in two patients with astrocytoma grade III and in one patient each with neuroblastoma and pleomorphic rhabdomyosarcoma, respectively.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


2. Ohta K, Kuwahara K, Zhang Z, Makino K, Komohara Y, Nakamura H, Kuratsu J, Sakaguchi N: Decreased expression of germinal center-associated nuclear protein is involved in chromosomal instability in malignant gliomas. Cancer Sci; 2009 Nov;100(11):2069-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of germinal center-associated nuclear protein is involved in chromosomal instability in malignant gliomas.
  • Malignant glioma (MG) is highly proliferative and invasive, with the malignant characteristics associated with aneuploidy and chromosomal instability (CIN).
  • Glioblastomas showed a significantly lower level of ganp mRNA than anaplastic astrocytomas, as measured by real-time reverse transcription-PCR, in 101 cases of adult MG.
  • MGs of ganp(Low) expression displayed more malignant characteristics, with loss of heterozygosity on chromosome 10, epidermal growth factor receptor gene amplification, and significantly poorer prognosis than the ganp(High) group.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Female. Genes, p53. Humans. Intracellular Signaling Peptides and Proteins. Loss of Heterozygosity. Male. Middle Aged. Mutation. RNA Interference. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686285.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / MCM3AP protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Montemor JP, Peria FM, Monti CR, Petrilli LS, Colli BO, Carlotti Júnior CG: Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. Onkologie; 2008 Sep;31(8-9):435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment.
  • BACKGROUND: Anaplastic astrocytomas (AA) and glioblastomas (GB) are the most common malignant gliomas, and despite newly developed drugs and combined treatments, they still have an adverse prognosis.
  • Paclitaxel is a cytotoxic agent with radiosensitizing properties and exerts objective growth inhibition in glioma tumor cells.
  • CONCLUSIONS: Chemoradiotherapy with weekly paclitaxel is safe and tolerable although there was no increase in the overall survival and 12-month survival of malignant glioma patients.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18787350.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T: Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol; 2005 Sep;55(3):393-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We examined 65 patients with histologically or clinically diagnosed brain tumors (12 low-grade gliomas, 31 high-grade gliomas, 14 metastatic tumors, and 8 lymphomas) using a 1.5 T MR unit.
  • RESULTS: The ADC(min) values of low-grade gliomas (1.09+/-0.20 x 10(-3)mm(2)/s) were significantly higher (p<.001) than those of other tumors.
  • There were no statistical significant differences between glioblastomas (0.70+/-0.16 mm(2)/s), anaplastic astrocytomas (0.77+/-0.21 mm(2)/s), metastases (0.78+/-0.21 mm(2)/s), and lymphomas.
  • But, lymphomas had lower mean ADC(min) values (0.54+/-0.10mm(2)/s) than high-grade gliomas and metastases.
  • CONCLUSION: The ADC measurements may help to differentiate low-grade gliomas from high-grade gliomas, metastases, and lymphomas.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Diagnosis, Differential. Female. Glioma / pathology. Humans. Lymphoma / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129247.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


5. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther; 2006 Mar;5(1):40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
  • Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG).
  • PATIENTS: The following group of 18 patients was evaluable: 4 patients with glioblastomas and 14 patients with anaplastic HBSG.
  • RESULTS: The overall survival at 2 and 5 years was 39% and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma.
  • Antineoplastons were tolerated very well with 1 case of grade 4 toxicity (reversible anemia).
  • CONCLUSION: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.
  • [MeSH-major] Benzeneacetamides / administration & dosage. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Glutamine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Phenylacetates / administration & dosage. Piperidones / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Female. Follow-Up Studies. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484713.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


6. Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, Eisenhauer EA: Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro Oncol; 2005 Apr;7(2):183-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group.
  • We studied the activity of T138067-sodium in patients with malignant gliomas.
  • Patients with recurrent anaplastic astrocytoma or glioblastoma multiforme were treated intravenously with 330 mg/m(2) of T138067-sodium weekly.
  • There were two patients with anaplastic astrocytoma and 16 with glioblastoma multiforme.
  • Our results suggest that given in this dose and schedule T138067-sodium does not have activity in this population of anaplastic astrocytoma and glioblastoma multiforme.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):613-24 [11300931.001]
  • [Cites] J Med Chem. 2001 Oct 25;44(22):3599-605 [11606124.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(4):CD003913 [12519620.001]
  • [Cites] Cell Motil Cytoskeleton. 2003 Sep;56(1):45-56 [12905530.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):O1-9 [11342188.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91 [10318945.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • (PMID = 15831236.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; T4NP8G3K6Q / batabulin
  • [Other-IDs] NLM/ PMC1871890
  •  go-up   go-down


7. Pogoda JM, Preston-Martin S, Howe G, Lubin F, Mueller BA, Holly EA, Filippini G, Peris-Bonet R, McCredie MR, Cordier S, Choi W: An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol; 2009 Mar;19(3):148-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group.
  • The cured meat association was specific to astrocytomas (odds ratio [OR] range=1.8-2.5 across astrocytoma subtypes for 4th vs. 1st quartile of consumption, p trends <or= 0.03) and ependymomas (OR, 2.0; 95% confidence interval (CI), 0.4-2.9 for 4th vs. 1(st) quartile; p trend=0.03) and was similar in magnitude to previously reported ORs relating maternal cured meat consumption to increased astroglial risk.
  • Other histology-specific associations were decreased risk of anaplastic astrocytomas from cruciferous vegetables (OR, 0.4; 95% CI, 0.3-0.7 for 4th vs. 1st quartile; p trend<0.0001), decreased risk of astroglial tumors from fresh fish (OR, 0.6; 95% CI, 0.5-0.9 for 4th vs. 1st quartile; p trend=0.008), and increased risk of medulloblastoma from oil products (OR, 1.5; 95% CI, 1.0-2.2 for 4th vs. 1(st) quartile; p trend=0.005).
  • CONCLUSIONS: These results suggest the need for dietary analysis not only by brain tumor histology, but also by specific foods within a broad food group.

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Brain Tumor, Childhood.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1136-42 [11744519.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):274-82 [11452935.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):173-90 [15476859.001]
  • [Cites] Z Krebsforsch. 1968;71(4):320-60 [4237278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Mar;71(3):639-43 [4522778.001]
  • [Cites] J Am Diet Assoc. 1979 Dec;75(6):647-65 [389993.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Arch Geschwulstforsch. 1981;51(2):187-203 [7271429.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:274-89 [6953795.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5240-5 [7139628.001]
  • [Cites] Recent Results Cancer Res. 1983;84:63-76 [6844702.001]
  • [Cites] IARC Sci Publ. 1983;(51):65-79 [6365774.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] IARC Sci Publ. 1989;(96):17-34 [2553598.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2608-12 [2328486.001]
  • [Cites] Br J Neurosurg. 1990;4(1):17-25 [2334522.001]
  • [Cites] In Vivo. 1990 Sep-Oct;4(5):327-35 [2133106.001]
  • [Cites] N Engl J Med. 1993 Aug 19;329(8):536-41 [8336753.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):11-5 [8262665.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):177-87 [8167265.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):769-74 [8206670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):197-204 [8019366.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):776-82 [7989118.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):17-48 [7600541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6941-6 [8692923.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):599-605 [8824361.001]
  • [Cites] Am J Clin Nutr. 1997 Apr;65(4 Suppl):1153S-1158S [9094913.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):688-97 [9328190.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:887-92 [9646053.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):635-8 [9681534.001]
  • [Cites] Biometrics. 1998 Sep;54(3):948-63 [9750244.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):198-203 [10207928.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] Cancer Causes Control. 2005 Aug;16(6):619-35 [16049800.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):877-91 [16132798.001]
  • [Cites] Ann Epidemiol. 2009 Mar;19(3):161-71 [19216998.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):595-602 [3752053.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):139-43 [10728608.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1157-62 [10837004.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):317-9 [11369736.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:669-73 [12092679.001]
  • (PMID = 19216997.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NCI NIH HHS / CA / P01 CA017054-30; United States / NCI NIH HHS / PC / N01 PC035139; United States / NCI NIH HHS / CA / CA47082; United States / NIEHS NIH HHS / ES / P30 ES007048-029003; United States / NCI NIH HHS / CA / CA47081; United States / NCI NIH HHS / CA / CA17054; United States / NCI NIH HHS / CN / N01-CN-05230; United States / NIEHS NIH HHS / ES / ES007048-029003; United States / NCI NIH HHS / CN / N01-CN-25403; United States / NCI NIH HHS / CA / P01 CA017054; United States / NCI NIH HHS / CA / N01 CN025403; United States / NCI NIH HHS / CN / N01 CN005230; United States / NIEHS NIH HHS / ES / 5P30 ES07048
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitroso Compounds
  • [Other-IDs] NLM/ NIHMS98974; NLM/ PMC2832584
  •  go-up   go-down


8. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A: Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery; 2009 Sep;65(3):463-9; discussion 469-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Balancing the benefits of extensive tumor resection with the consequence of potential postoperative deficits remains a challenge in malignant astrocytoma surgery.


9. Choi YL, Kim CJ, Matsuo T, Gaetano C, Falconi R, Suh YL, Kim SH, Shin YK, Park SH, Chi JG, Thiele CJ: HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J Neurooncol; 2005 May;73(1):19-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten human brains at different developmental stages and 118 cases of nervous system tumor tissues were examined by immunohistochemistry.
  • Twelve related tumor cell lines were also analyzed by northern blotting and immunoblotting.
  • Among tumors, hUlip expression was easily detected in tumor cells undergoing neuronal differentiation such as ganglioneuroblastomas and ganglioneuromas.
  • Furthermore, hUlip immunoreactivity was also found in various brain tumors showing neuronal differentiation: central neurocytomas (6 of 6 cases were positive), medulloblastomas (5/11), atypical teratoid rhabdoid tumor (1/1) and gangliogliomas (4/7).
  • Some astrocytic tumors also showed weak positivity: astrocytomas (1 of 5 cases), anaplastic astrocytomas (2/5), and glioblastomas (3/11).
  • Subependymal giant cell astrocytomas and subependymomas, which are of controversial histogenetic origin, showed strong hUlip immunoreactivity.
  • [MeSH-minor] Astrocytes / cytology. Astrocytes / metabolism. Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. Female. Gestational Age. Humans. Immunohistochemistry. Male. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neurons / cytology. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4226-32 [10594648.001]
  • [Cites] Lab Invest. 1990 Apr;62(4):498-509 [2159086.001]
  • [Cites] Brain Dev. 1998 Mar;20(2):88-94 [9545178.001]
  • [Cites] Brain Res Dev Brain Res. 1997 Sep 20;102(2):305-8 [9352115.001]
  • [Cites] Genetics. 1992 Nov;132(3):675-89 [1468626.001]
  • [Cites] J Neuroophthalmol. 2001 Sep;21(3):164-7 [11725180.001]
  • [Cites] Brain Dev. 1999 Jan;21(1):41-50 [10082252.001]
  • [Cites] Dev Biol. 1985 Sep;111(1):158-70 [3928418.001]
  • [Cites] Annu Rev Neurosci. 1995;18:385-408 [7605067.001]
  • [Cites] Brain Res. 2002 Oct 18;952(2):153-8 [12376175.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2815-23 [12684468.001]
  • [Cites] Neuron. 1994 Oct;13(4):805-11 [7524558.001]
  • [Cites] Lab Invest. 1989 Dec;61(6):635-43 [2557487.001]
  • [Cites] Biol Neonate. 1996;69(4):257-67 [8724654.001]
  • [Cites] Cereb Cortex. 1996 Nov-Dec;6(6):794-806 [8922336.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):405-16 [6589432.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):157-63 [8973361.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):175-82 [10721710.001]
  • [Cites] Hum Genet. 1996 Feb;97(2):240-3 [8566961.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12195-201 [9115293.001]
  • [Cites] J Neurosci. 1995 Oct;15(10):6757-66 [7472434.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1079-87 [2161798.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6197-207 [8815901.001]
  • [Cites] Acta Neuropathol. 1986;70(3-4):320-6 [3020862.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2197-211 [1544125.001]
  • [Cites] J Comp Neurol. 1995 May 8;355(3):369-79 [7636019.001]
  • [Cites] Neuropathol Appl Neurobiol. 1984 Jan-Feb;10(1):63-75 [6738805.001]
  • [Cites] Nature. 1995 Aug 10;376(6540):509-14 [7637782.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):574-80 [9181582.001]
  • [Cites] Neuron. 1993 Aug;11(2):321-31 [8394722.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24725-31 [7559588.001]
  • (PMID = 15933812.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DPYSL3 protein, human; 0 / Muscle Proteins
  •  go-up   go-down


10. Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U, Hawkins CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer; 2005 Oct 1;104(7):1487-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Better treatments are required urgently for patients with malignant glioma, which currently is incurable.
  • Death ligands, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), may offer promise for the treatment high-grade glioma if such ligands induce apoptotic signaling in vivo in glioma cells.
  • It also may act as a tumor suppressor protein.
  • METHODS: Eleven glioblastomas, 5 anaplastic astrocytomas, and 3 low-grade astrocytomas were studied.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / pathology. Caspases / metabolism. Glioblastoma / pathology
  • [MeSH-minor] Base Sequence. Blotting, Northern. Caspase 10. Caspase 8. DNA Methylation. DNA, Neoplasm / analysis. Female. Humans. Male. Molecular Sequence Data. Probability. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Statistics, Nonparametric. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080161.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CASP10 protein, human; 0 / DNA, Neoplasm; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 10; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


11. Nakabayashi H, Hara M, Shimizu K: Prognostic significance of CDC25B expression in gliomas. J Clin Pathol; 2006 Jul;59(7):725-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty seven gliomas, which included 21 low-grade astrocytomas, 17 anaplastic astrocytomas and 19 glioblastomas, were studied.
  • RESULTS: High expression of CDC25B was identified in 18 of the 19 glioblastomas, in 10 of the 17 anaplastic astrocytomas, but not in any of the 21 low-grade astrocytomas.
  • The CDC25B mRNA expression increased with the rise in histological grade.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Glioma / metabolism. cdc25 Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / metabolism. Astrocytoma / pathology. Female. Gene Expression. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1994 Apr 1;13(7):1549-56 [8156993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2917-21 [1372994.001]
  • [Cites] Science. 1995 Sep 15;269(5230):1575-7 [7667636.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5025-9 [7585546.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):511-7 [8700224.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):1081-93 [8743955.001]
  • [Cites] J Cell Biol. 1997 Sep 8;138(5):1105-16 [9281587.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28607-14 [9353326.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1762-7 [9563496.001]
  • [Cites] J Cell Sci. 1998 Aug;111 ( Pt 16):2445-53 [9683638.001]
  • [Cites] J Cell Biol. 1999 Aug 9;146(3):573-84 [10444066.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3043-50 [10850455.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4835-40 [11205229.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35176-82 [12107172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5139-43 [2195549.001]
  • [Cites] Nature. 1991 Feb 28;349(6312):808-11 [1825699.001]
  • [Cites] New Biol. 1991 Oct;3(10):959-68 [1662986.001]
  • [Cites] Genes Dev. 1995 May 1;9(9):1046-58 [7744247.001]
  • (PMID = 16803948.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.3.16 / CDC25B protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  • [Other-IDs] NLM/ PMC1860415
  •  go-up   go-down


12. Paulino AC, Mai WY, Chintagumpala M, Taher A, Teh BS: Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys; 2008 Aug 1;71(5):1381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced malignant gliomas: is there a role for reirradiation?
  • PURPOSE: To review the literature regarding the role of radiotherapy (RT) in the treatment of patients with radiation-induced malignant gliomas (RIMGs).
  • RESULTS: Initial tumor types treated with RT included brain tumor in 37 patients (40%), acute lymphoblastic leukemia in 33 (36%), benign disease in 11 (12%), and other in 11 (12%).
  • Type of RIMG was glioblastoma in 69 (75%) and anaplastic astrocytoma in 23 (25%).
  • One-, 2-, and 5-year overall survival rates were 29.3%, 7.3%, and 0% for patients with glioblastoma and 59.7%, 30.3%, and 20.2% for patients with anaplastic astrocytoma.
  • [MeSH-minor] Astrocytoma / radiotherapy. Glioblastoma / radiotherapy. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Retreatment. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):304-5; author reply 305 [18722290.001]
  • (PMID = 18262733.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


13. Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, Perry A, Tibbetts KM, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH: Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol; 2008 Dec;67(12):1194-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.
  • Pilocytic astrocytomas (PAs) are World Health Organization Grade I gliomas; they most often affect children and young adults and occur in patients with neurofibromatosis type 1 (NF1).
  • Furthermore, in an additional independent set of tumors, weak to absent ALDH1L1 expression was found in 13 (72%) of 18 clinically aggressive PAs, in 8 (89%) of 9 PAs with pilomyxoid features, in 7 (70%) of 10 PAs with anaplastic transformation, and in 16 (76%) of 21 diffusely infiltrating astrocytomas of various grades.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 13;297(1):148-53 [12220523.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4073-9 [11751504.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):996-1001 [11958894.001]
  • [Cites] Cell Growth Differ. 2002 May;13(5):227-36 [12065246.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] J Comp Neurol. 2007 Jan 10;500(2):368-83 [17111379.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]
  • [Cites] J Neurooncol. 2008 Jan;86(2):183-90 [17690840.001]
  • [Cites] J Neurosci. 2008 Jan 2;28(1):264-78 [18171944.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Mar;67(3):240-9 [18344915.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1235-44 [18325984.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1394-9 [18550570.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Jan;266(1):89-96 [18427826.001]
  • [Cites] Liver Int. 2009 Feb;29(2):187-95 [18694400.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:504-9 [15033780.001]
  • [Cites] Melanoma Res. 2004 Feb;14(1):29-37 [15091191.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] J Biol Chem. 1989 Jan 5;264(1):328-33 [2909524.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2291-5 [1707749.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1335-42 [8339223.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):9-16 [9525833.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1511-6 [9865840.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8796-804 [15467732.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Biochem J. 2005 Nov 1;391(Pt 3):503-11 [16014005.001]
  • [Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36216-22 [12147692.001]
  • (PMID = 19018242.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NINDS NIH HHS / NS / T32 NS007494; United States / NINDS NIH HHS / NS / NS007494-05; United States / NINDS NIH HHS / NS / T32 NS07494-04; United States / NINDS NIH HHS / NS / T32 NS007494-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Nerve Tissue Proteins; EC 1.2.1.- / aldehyde dehydrogenase 1; EC 1.2.1.3 / Aldehyde Dehydrogenase; EC 1.2.1.36 / Retinal Dehydrogenase; EC 1.5.1.6 / ALDH1L1 protein, human
  • [Other-IDs] NLM/ NIHMS87254; NLM/ PMC2730602
  •  go-up   go-down


14. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C: Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci; 2008 Feb;15(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
  • Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma.
  • We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Dendritic Cells / immunology. Immunotherapy, Active / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083572.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Cancer Vaccines; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


15. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
  • The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
  • The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined for astrocytic tumors.
  • Receiver operating characteristics (ROC) analysis of T/N and standardized uptake value (SUV) was performed for the group of astrocytic tumors.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.
  • For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV.
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.


16. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Methylation. Female. Glioblastoma / drug therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


17. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL: Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res; 2005 Jul 1;65(13):5535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
  • As we have found that Lyn, but not Fyn, activity promotes migration of glioblastoma cells in response to the cooperative signal generated by platelet-derived growth factor receptor beta and integrin alpha(v)beta3, we compared the activity and expression of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma (grade III) tumors, nonneoplastic brain, and normal autopsy brain samples.
  • Lyn kinase activity was significantly elevated in glioblastoma tumor samples.
  • The levels of phosphorylation of the autophosphorylation site were consistent with significantly higher Lyn activity in glioblastoma tumor tissue than nonneoplastic brain.
  • Immunostaining revealed that Lyn is located primarily in the glioblastoma cells in the tumor biopsies.
  • These data indicate that Lyn kinase activity is significantly elevated in glioblastoma tumors and suggest that it is the Lyn activity that promotes the malignant phenotype in these tumors.
  • [MeSH-minor] Astrocytoma / enzymology. Astrocytoma / genetics. Astrocytoma / pathology. Biopsy. Brain / enzymology. Endothelial Cells / enzymology. Humans. Immunohistochemistry. Phosphotransferases / genetics. Phosphotransferases / metabolism. Protein-Tyrosine Kinases. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-fyn. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994925.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97110; United States / NCI NIH HHS / CA / P50 CA97247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / CSK tyrosine-protein kinase; EC 2.7.10.2 / FYN protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fyn; EC 2.7.10.2 / lyn protein-tyrosine kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


18. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol; 2010 Dec;100(3):449-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.
  • Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined.
  • We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV).
  • In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels.
  • PEA-15 expression level was inversely associated with WHO grade (P = 0.0006).
  • Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level.
  • Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024).
  • In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / metabolism. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Health Statistics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurosci. 1999 Oct 1;19(19):8244-51 [10493725.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25020-5 [11976344.001]
  • [Cites] Radiother Oncol. 2007 Dec;85(3):371-8 [18035440.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7012-21 [16044159.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1155-66 [17700518.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):5005-15 [15143191.001]
  • [Cites] J Neurochem. 1998 Sep;71(3):1307-14 [9721757.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4511-21 [12808093.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):729-35 [15916534.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1536-44 [17308092.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4409-15 [10442631.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2416-26 [18284607.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):239-50 [11702783.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3552-61 [15917297.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9302-10 [19010903.001]
  • [Cites] Neuropathology. 2008 Oct;28(5):507-15 [18410277.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5911-20 [8449955.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12840-7 [14707138.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1491-9 [16452205.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1215-22 [17192900.001]
  • (PMID = 20455002.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / PEA15 protein, human; 0 / Phosphoproteins
  •  go-up   go-down


19. Nano R, Capelli E, Facoetti A, Benericetti E: Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res; 2009 Jul;29(7):2461-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunobiological and experimental aspects of malignant astrocytoma.
  • Starting from 1992, the goal of our studies was to obtain new biological data on malignant astrocytomas to better understand the basic biology of the tumour and these are reviewed here.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596914.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 51
  •  go-up   go-down


20. Jeannin S, Lebrun C, Van Den Bos F, Olschwang S, Bourg V, Frenay M: [Turcot's syndrome confirmed by molecular biological tests]. Rev Neurol (Paris); 2006 Jun;162(6-7):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Syndrome de Turcot confirmé par biologie moléculaire.
  • INTRODUCTION: Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and a familial adenomatous polyposis or a hereditary nonpolyposis colorectal cancer.
  • OBSERVATION: We report a case of a 45-year-old woman who underwent in 1995 neuro-oncological treatment for an anaplastic astrocytoma (grade III according to the World Health Organization classification).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840983.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


21. Ghostine B, Ali Y, Menassa L, Okais N, Nohra G, Rizk T, Maarawi J, Samaha E, Moussa R: [Brain tumors and epilepsy: postoperative evaluation of surgical procedures]. J Med Liban; 2010 Apr-Jun;58(2):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evolution postopératoire de l'epilepsie chez les patients opérés de tumeurs cérébrales.
  • METHODS: Forty patients operated for supratentoriel cerebral tumors with epilepsy, at Hotel-Dieu de France (HDF) hospital center, between 1983 and 2005, were included in this study.
  • The extent of the tumor resection was based on the postoperative MRI results.
  • The histopathologic exam revealed 2 DNET, 3 pilocytic astrocytomas, 2 diffuse astrocytomas, 6 A oligodendrogliomas, 7 B oligodendrogliomas, 7 anaplastic astrocytomas and glioblastomas and 13 meningiomas.
  • The prognostic factors of good outcome were: low-grade glial tumors (I +/- II), meningiomas, and complete tumor resection.
  • This control depended essentially on the extent of tumor resection and on tumor's nature.


22. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K: Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol; 2007 Apr;82(2):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
  • OBJECTIVE: Subcellularly localized (nuclear and/or cytoplasmic) survivin has various functions, and correlates with prognosis of malignant tumors.
  • However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas.
  • The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma.
  • METHODS: We immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas).
  • We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor).
  • CONCLUSIONS: We found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma.
  • The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Subcellular Fractions. Survival Rate. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):401-7 [15241527.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):151-6 [15925995.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):44-53 [11925104.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):379-82 [12711293.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3531-4 [15867343.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2723-34 [15735764.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):115-9 [12556969.001]
  • [Cites] Cancer Lett. 2001 Feb 10;163(1):109-16 [11163114.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Cell Death Differ. 2002 Dec;9(12):1334-42 [12478470.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):501-10 [14742256.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Acta Oncol. 2003;42(5-6):582-8 [14596516.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):212-6 [15611788.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):108-14 [16404364.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii27-9 [16760287.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1378-85 [15195112.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1077-83 [12671708.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Mol Cancer. 2005 Mar 02;4(1):11 [15743529.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):509-12 [15578717.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1654-60 [15520067.001]
  • (PMID = 17151933.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / epidermal growth factor receptor-neu receptor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Tuominen H, Lohi J, Maiche A, Törmänen J, Baumann P: Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma. J Neurooncol; 2005 Nov;75(2):225-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Follow-Up Studies. Gene Deletion. Genes, p16. Glial Fibrillary Acidic Protein / metabolism. Homozygote. Humans. Male. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1778-82 [4027909.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(5-6):342-9 [8729851.001]
  • [Cites] J Neurosurg. 1971 May;34(5):697-701 [4326303.001]
  • [Cites] Digestion. 2000;61(3):219-22 [10773729.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):498-507 [12147436.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2):297-300 [11807444.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):107-14 [11716064.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]
  • (PMID = 16132499.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


24. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


25. Da Fonseca CO, Silva JT, Lins IR, Simão M, Arnobio A, Futuro D, Quirico-Santos T: Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs; 2009 Dec;27(6):557-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
  • BACKGROUND: The aim of this study was to establish a correlation of tumor topography and peritumoral brain edema with the therapeutic response to intranasal administration of perillyl alcohol (POH) in a cohort of patients with recurrent malignant gliomas.
  • METHODS: The retrospective study reviewed clinical and neuroradiological data from patients with recurrent malignant gliomas who received intranasal daily administration of POH 440 mg.
  • The following parameters were assessed: demographic characteristics, initial symptoms, overall survival, tumor topography and tumor size, presence of midline shift and extent of peritumoral edema.
  • RESULTS: A cohort of 67 patients included 52 (78%) with glioblastoma (GBM), ten (15%) with anaplastic astrocytoma (AA) and five (7%) with anaplastic oligodendroglioma (AO).
  • Accordingly to tumor topography lobar localization was present in all (5/5) AO; eight (8/10) and 41 GBM patients whereas in the basal ganglia two AA and 11 GBM patients.
  • It was also observed a relation between the tumor size and area of peritumoral brain edema (PTBE).
  • Patients with good therapeutic response showed reduction of tumor size and PTBE area, but poor prognosis was associated with lack of response to treatment and persistence of high PTBE.
  • Patients with tumor in the basal ganglia survived significantly longer than those with lobar gliomas (log rank test, p = 0.0003).
  • (2) presence of PTBE contributes to symptoms, likely to be implicated in the morbidity and invading potential of malignant gliomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Edema / pathology. Brain Neoplasms / drug therapy. Glioma / drug therapy. Glioma / pathology. Monoterpenes / therapeutic use. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Neurol. 2005 Jul;4(7):413-22 [15963444.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Mar;28(3):462-9 [17353313.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):65-73 [8699228.001]
  • [Cites] J BUON. 2007 Apr-Jun;12(2):239-43 [17600879.001]
  • [Cites] Vojnosanit Pregl. 2003 Mar-Apr;60(2):147-54 [12852156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1359-62 [11121634.001]
  • [Cites] Surg Neurol. 2006;65 Suppl 1:S1:2-1:8; discussion S1:8-1:9 [16427438.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):760-9 [17460461.001]
  • [Cites] Surg Neurol. 2006 Dec;66(6):611-5 [17145324.001]
  • [Cites] Am J Dermatopathol. 2008 Aug;30(4):381-4 [18645311.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):267-76 [18726148.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] J Neurol Sci. 2007 Sep 15;260(1-2):49-56 [17475281.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):211-7 [15980971.001]
  • [Cites] Neurol India. 2002 Mar;50(1):37-40 [11960149.001]
  • [Cites] Glia. 2008 Jun;56(8):917-24 [18383343.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7 [18295834.001]
  • [Cites] Bull Mem Acad R Med Belg. 2007;162(5-6):331-8 [18405003.001]
  • [Cites] Bull Cancer. 2008 Jan;95(1):51-6 [18230570.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Acta Neurochir Suppl. 2003;85:47-53 [12570137.001]
  • [Cites] J Neurol Sci. 2003 Dec 15;216(1):1-10 [14607296.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):1-9 [17204931.001]
  • [Cites] Onkologie. 2004 Jun;27(3):261-6 [15249715.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • (PMID = 19139816.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Monoterpenes; 319R5C7293 / perillyl alcohol
  •  go-up   go-down


26. Roma AA, Prayson RA: Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology; 2006 Oct;26(5):422-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up-regulation of cyclo-oxygenase-2 (COX-2), a cytokine-induced enzyme that metabolizes arachidonic acid into prostaglandins, has been described in some brain tumors, including astrocytomas.
  • The study group (56 men and 44 women, mean age, 30.8 years) was comprised of 48 low-grade ependymomas (WHO grade II), 12 anaplastic ependymomas (WHO grade III), 27 myxopapillary ependymomas (WHO grade I) and 13 subependymomas (WHO grade I).
  • At last known follow-up (range, 12-226 months; mean, 74 months), 52 patients were alive with no evidence of tumor, 16 patients were alive with residual tumor, nine patients died with tumor, one patient died with no tumor and three died with tumor status unknown.
  • Thirty-six (36%) patients had tumors, which demonstrated positive COX-2 staining, including 16/27 (59%) myxopapillary ependymomas, 3/13 (23%) subependymomas, 14/48 (29%) ependymomas and 3/12 (25%) anaplastic ependymomas.
  • Statistically significant COX-2 positive immunostaining was observed in myxopapillary ependymomas versus WHO grade II (P = 0.03) and grade III (P = 0.02) tumors.
  • Increased COX-2 expression in myxopapillary ependymoma as compared to the WHO grade II and II ependymoma was observed.
  • The reason for this apparent increased immunoexpression in these low-grade tumors is uncertain.
  • COX-2 staining did not reliably predict tumor behavior.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cyclooxygenase 2 / biosynthesis. Ependymoma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080719.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Raza SM, Garzon-Muvdi T, Boaehene K, Olivi A, Gallia G, Lim M, Subramanian P, Quinones-Hinojosa A: The supraorbital craniotomy for access to the skull base and intraaxial lesions: a technique in evolution. Minim Invasive Neurosurg; 2010 Feb;53(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-axial pathology ranged from anaplastic astrocytoma to metastasis while extra-axial lesions included meningiomas and skull-based metastases.
  • [MeSH-minor] Adenoma / surgery. Astrocytoma / surgery. Breast Neoplasms / surgery. Craniopharyngioma / surgery. Esthetics. Eyebrows. Eyelids. Female. Follow-Up Studies. Frontal Lobe / surgery. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / surgery. Postoperative Complications / etiology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20376737.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Kim JH, Choi C, Benveniste EN, Kwon D: TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun; 2008 Dec 5;377(1):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells.
  • Matrix metalloproteinase-9 (MMP-9) is an important angiogenic and prognostic factor in malignant tumors.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed tumor cells.
  • We demonstrated that TRAIL induces MMP-9 expression in human astrocytoma cells, which is preceded by activation of extracellular signal-regulated protein kinase (ERK).
  • These findings indicate that TRAIL treatment in human astrocytoma cells leads to the activation of NF-kappaB and subsequent expression of MMP-9, which are dependent on ERK activation.
  • Collectively, these results suggest that TRAIL has alternative biological functions in addition to its role in inducing apoptosis in human malignant astrocytoma cells.
  • [MeSH-major] Astrocytoma / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Matrix Metalloproteinase 9 / biosynthesis. TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Butadienes / pharmacology. Cell Line, Tumor. Enzyme Activation. Humans. NF-kappa B / metabolism. Nitriles / pharmacology. Protein Kinase Inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834856.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / NF-kappa B; 0 / Nitriles; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / U 0126; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


29. Tanaka S, Kobayashi I, Utsuki S, Iwamoto K, Takanashi J: Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. Neurol Med Chir (Tokyo); 2005 Jan;45(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Partial resection of the tumor was safely performed, with slight temporary neurological worsening.
  • The histological diagnosis was anaplastic astrocytoma.
  • Individual adjuvant therapy based on the results of real-time reverse transcription-polymerase chain reaction of O6-methylguanine-deoxyribonucleic acid methyltransferase achieved an almost complete tumor response.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping. Brain Stem Neoplasms / surgery. Evoked Potentials, Motor. Mesencephalon / physiopathology. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699622.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A; 2007 Jul 10;104(28):11736-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies show that IGFBP2 coexpression results in progression to a higher-grade glioma in platelet-derived growth factor beta (PDGFB)-driven tumors.
  • These anaplastic oligodendrogliomas are characterized by increased cellularity, vascular proliferation, small regions of necrosis, increased mitotic activity, and increased activation of the Akt pathway.
  • Combined expression of IGFBP2 or Akt with K-Ras was required to form astrocytomas, indicating that activation of two separate pathways is necessary for gliomagenesis.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Eur J Pediatr. 1996 Feb;155(2):81-6 [8775218.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2308-13 [9215312.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1218-23 [9448312.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]
  • [Cites] Eur Urol. 2005 May;47(5):695-702 [15826765.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3022-7 [15687344.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):356-68 [15967113.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):397-406 [15967117.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):657-64 [16699322.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14085-91 [16569642.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7429-37 [16885338.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Growth Horm IGF Res. 2006 Aug;16(4):224-39 [16893667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3414-9 [17360660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5563-8 [17372210.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6289-96 [17438529.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:101-27 [11008486.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7100-13 [12370832.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):824-54 [12466191.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1796-806 [15014034.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):859-68 [15171717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1031-5 [7682560.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] Int J Cancer. 1994 May 15;57(4):491-7 [7514152.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • (PMID = 17606927.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098503; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA- 16672; United States / NCI NIH HHS / CA / R01 CA98503; United States / NIDDK NIH HHS / DK / 5 T90 DK070109-02; United States / NIDDK NIH HHS / DK / T90 DK070109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC1913900
  •  go-up   go-down


31. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res; 2008 Nov 1;68(21):8733-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found that FoxM1B is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly angiogenic glioblastoma in nude mice.
  • Our findings provide both clinical and mechanistic evidence that FoxM1 contributes to glioma progression by enhancing VEGF gene transcription and thus tumor angiogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4143-54 [11358838.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8404-13 [12466961.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):123-30 [15018896.001]
  • [Cites] Genes Dev. 2004 Apr 1;18(7):830-50 [15082532.001]
  • [Cites] BMC Cancer. 2003 Sep 17;3:23 [13678425.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324 [15450248.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5363-8 [7565686.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):41-9 [8817614.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1626-41 [9032290.001]
  • [Cites] Nucleic Acids Res. 1997 May 1;25(9):1715-9 [9108152.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19827-36 [9242644.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3860-4 [9288800.001]
  • [Cites] Mol Biol Cell. 1998 Feb;9(2):469-81 [9450968.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):118-24 [10077162.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22278-86 [15817462.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1712-20 [16452231.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3593-602 [16585184.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1420-31 [17408638.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6212-9 [17404569.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2562-72 [10873113.001]
  • (PMID = 18974115.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA116528-03; United States / NCI NIH HHS / CA / CA116528-03; United States / NCI NIH HHS / CA / R01-CA-116528; United States / NCI NIH HHS / CA / R01 CA116528; United States / NCI NIH HHS / CA / R01 CA116528-02; United States / NCI NIH HHS / CA / CA116528-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS67455; NLM/ PMC2597644
  •  go-up   go-down


32. Sathornsumetee S, Rich JN, Reardon DA: Diagnosis and treatment of high-grade astrocytoma. Neurol Clin; 2007 Nov;25(4):1111-39, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of high-grade astrocytoma.
  • High-grade astrocytomas include the most common adult central nervous system (CNS) tumor, glioblastoma multiforme, and anaplastic astrocytoma--a highly aggressive cancer with short median survival despite maximal multimodality therapy.
  • Nearly all patients who have high-grade astrocytomas develop tumor recurrence or progression after this multimodality treatment.
  • Two treatment challenges are molecular/genetic heterogeneity of tumors and limited CNS tumor delivery.
  • This article discusses diagnosis and current treatment of high-grade astrocytomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / pathology. Astrocytoma / therapy. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Brachytherapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neoplasm Staging. Neurosurgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964028.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 142
  •  go-up   go-down


33. Murakami H, Sawa H, Kamada H: [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]. No To Shinkei; 2006 Jan;58(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors].
  • Cyclooxygenase (COX)-2 of astrocytic tumors was studied by immunohistochemistry.
  • COX-2 was expressed in 8 of 12 (75%) glioblastoma multiforme, 1 of 7 (14%) anaplastic astrocytoma, but none in astrocytoma.
  • The result showed that COX-2 expression may be related with histological grades and COX-2 inhibitors will be one of promising therapeutic tools in human astrocytic tumors.
  • [MeSH-major] Astrocytoma / enzymology. Cyclooxygenase 2 / analysis. Cyclooxygenase 2 Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Aged. Etodolac / pharmacology. Female. Glioblastoma / drug therapy. Glioblastoma / enzymology. Humans. Immunoblotting. Immunohistochemistry. Male. Middle Aged. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482921.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 2M36281008 / Etodolac; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


34. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


35. Tilleul P, Brignone M, Hassani Y, Taillandier L, Taillibert S, Cartalat-Carel S, Borget I, Chinot O: [Prescription guidebook for temozolomide usage in brain tumors]. Bull Cancer; 2009 May;96(5):579-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Guide de prescription et de bon usage du témozolomide dans les tumeurs cérébrales.
  • Malignant gliomas are the most frequent primary brain tumors in adults.
  • Temozolomide is an oral alkylating cytotoxic agent of second generation, used in the treatment of high-grade gliomas.
  • It is indicated in newly diagnosed glioblastoma multiform as well as in recurrent or progressive malignant gliomas, such as glioblastoma multiform or anaplastic astrocytoma.
  • The literature review was analysed by experts who determined the evidence level (A to E) according to the scale of recommendations adopted by the "Haute Autorité de santé--HAS--(French National Authority for Health)".
  • For high-grade and low-grade gliomas, based on the level of evidence from the literature, the use of temozolomide can be justified, with a B2 score attributed to these indications.
  • [MeSH-minor] Age Factors. Astrocytoma / drug therapy. Drug Administration Schedule. Drug Labeling. Glioblastoma / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467988.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Practice Guideline; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 55
  •  go-up   go-down


36. Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK: Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep; 2007 Jun;17(6):1359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
  • We analyzed the clinical efficacy and toxicity of concurrent therapy as a first line modality for malignant glioma patients.
  • From 1998 to 2004, 39 patients, 22 with glioblastoma (GM), nine with anaplastic astrocytoma (AA), 7 with anaplastic oligodendroglioma (AO) and 1 with anaplastic oligodendro-astrocytoma (AOA) were enrolled in this study.
  • Grade III/IV hematological toxicity was reduced from 25.6 to 13% after reduction of the dose of CCNU (75 mg/m(2)).
  • Modified concurrent chemoradiotherapy may be a feasible option for treating malignant glioma with acceptable toxicity.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487391.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


37. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • More recently, case reports have described malignant gliomas arising after irradiation and recurrences following subtotal or even gross total resection.
  • Nonetheless, a probably radiation induced anaplastic astrocytoma was encountered in one case 7 years after therapy.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology


38. Anselmo NP, Rey JA, Almeida LO, Custódio AC, Almeida JR, Clara CA, Santos MJ, Casartelli C: Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet Mol Res; 2009;8(4):1257-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
  • Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies.
  • Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.
  • The mutation found at exon 6 of the gene TP53 could be associated with the rapid tumoral progression found in this case, since the mutated p53 may inactivate the wild-type p53 and the p73alpha protein, which was conserved here, leading to an increase in cellular instability.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876867.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


39. Beauchesne PD, Taillandier L, Bernier V, Carnin C: Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. Cancer Chemother Pharmacol; 2009 Jun;64(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
  • PURPOSE: Fotemustine is a nitrosourea compound used for the treatment of malignant gliomas, especially in France.
  • We set out to test a concurrent combination of radiotherapy and fotemustine for newly malignant gliomas.
  • Patients over 18 years of age able to give informed consent and with histologically proven, newly diagnosed supratentorial malignant gliomas were eligible.
  • All patients were treated by a standard cranial irradiation (conformal irradiation, tumor bulk plus a margin of 2.5 cm) and concomitant daily administration of 10 mg/m(2) of fotemustine (5 days per week, 6 weeks, 1 h 30 min before radiation therapy).
  • Adjuvant chemotherapy, fotemustine, was administered at tumor progression as standard and classic regimen.
  • Histology included 16 glioblastomas, 3 anaplastic astrocytomas, 2 anaplastic oligodendrogliomas and 1 mixed glioma.
  • The concurrent radiotherapy-fotemustine combination was well tolerated: toxicity was mild and three hematologic toxicities grade 3-4 were observed.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352662.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


40. Dreyfuss JM, Johnson MD, Park PJ: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer; 2009 Sep 04;8:71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.
  • BACKGROUND: Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal.
  • A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas.
  • Although genomewide profiling of expression levels with microarrays can be used to identify differentially expressed genes between these tumor types, comparative studies so far have resulted in gene lists that show little overlap.
  • CONCLUSION: We have performed a meta-analysis of genome-scale mRNA expression data for 289 human malignant gliomas and have identified a list of >900 probe sets and >20 pathways that are significantly different between GBM and AA.
  • These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):848-62 [10847587.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] BMC Bioinformatics. 2008;9:63 [18226260.001]
  • [Cites] Genomics. 2008 May;91(5):395-406 [18343632.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 5;373(4):539-44 [18590702.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] BMC Bioinformatics. 2009;10:1 [19118496.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] FASEB J. 2001 Feb;15(2):458-66 [11156961.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Genome Biol. 2003;4(4):210 [12702200.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3166-78 [15231529.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Nat Methods. 2005 May;2(5):345-50 [15846361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]
  • [Cites] Comput Biol Chem. 2008 Feb;32(1):38-46 [17988949.001]
  • [Cites] Bioinformatics. 2008 Feb 1;24(3):374-82 [18204063.001]
  • [Cites] Ann Vasc Surg. 2008 Mar;22(2):273-84 [18346582.001]
  • (PMID = 19732454.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM082798; United States / NIH HHS / OD / DP2 OD002319; United States / NIH HHS / OD / DP2OD002319; United States / NLM NIH HHS / LM / U54 LM008748; United States / NLM NIH HHS / LM / U54LM008748
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2743637
  •  go-up   go-down


41. Serrano J, Rayo JI, Infante JR, Domínguez L, García-Bernardo L, Durán C, Fernández Portales I, Cabezudo JM: Radioguided surgery in brain tumors with thallium-201. Clin Nucl Med; 2008 Dec;33(12):838-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Malignant astrocytomas show thallium uptake with a high target-to-background ratio, allowing the use of radioguided surgery.
  • METHOD: We report on 6 patients (3 men) diagnosed with malignant astrocytoma.
  • With the gamma probe we confirmed the tumor uptake, and a biopsy sample was taken.
  • After conventional tumor resection, we scanned the surgical bed with the gamma probe.
  • RESULTS: In all patients the biopsy confirmed a high-grade astrocytoma.
  • In all cases we found residual uptake in the surgical bed that was confirmed as residual tumor by pathologic examination.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033782.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


42. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res; 2005 Jan 1;11(1):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
  • PURPOSE: The activator protein (AP)-2alpha transcription factor plays a crucial role in the progression of several human tumors, including malignant melanoma, prostate, and breast cancer.
  • Anderson Cancer Center since 1986 to include 72 glioblastomas, 49 anaplastic astrocytomas, 9 low-grade astrocytoma, 37 oligodendrogliomas, 37 anaplastic oligodendrogliomas, 15 mixed oligoastrocytomas, 20 anaplastic mixed oligoastrocytomas, and 7 gliosarcomas.
  • RESULTS: AP-2alpha expression was lost on 99% (P < 0.001) and 98% (P < 0.001) of glioblastomas and anaplastic astrocytomas, respectively, compared with grade 2 astrocytomas and normal brain, all of which (100%) maintained expression of AP-2alpha.
  • However, there was no significant effect of loss of AP-2alpha expression on survival observed after adjustment for patient age, Karnofsky Performance Scale score, tumor grade, and extent of resection (rate ratio, 1.2; 95% confidence interval, 0.6-2.2; P = 0.6).
  • CONCLUSIONS: AP-2alpha expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity, possibly through subsequent deregulation of target genes.
  • Of all the previously characterized markers of progression, the loss of AP-2alpha would be the most common (96.2%) molecular marker as an astrocytic tumor evolves from grade 2 to 3.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Motifs. Antigens, CD / biosynthesis. Antigens, CD146. Astrocytoma / metabolism. Brain / metabolism. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p21. Disease Progression. Humans. Immunohistochemistry. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Neural Cell Adhesion Molecules / biosynthesis. Oligodendroglioma / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-kit / biosynthesis. Time Factors. Transcription Factor AP-2. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / T-32-09666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / MCAM protein, human; 0 / Neural Cell Adhesion Molecules; 0 / TFAP2A protein, human; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


43. Bozinov O, Kalk JM, Krayenbühl N, Woernle CM, Sure U, Bertalanffy H: Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir (Tokyo); 2010;50(8):617-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
  • This gene is highly expressed in various types of human tumors including malignant gliomas.
  • The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy.
  • The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805641.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actins; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0S726V972K / Nimustine; 63231-63-0 / RNA; 957E6438QA / Teniposide
  •  go-up   go-down


44. Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F, Yung WK, Zhou YH: PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res; 2006 Oct 15;66(20):9809-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most invasive brain tumor.
  • By an in vitro Matrigel invasion assay on two GBM cell lines stably transfected with wild-type and/or two mutant forms of PAX6, this study displays the first evidence that PAX6 inhibits the invasiveness of GBM cells and that the DNA-binding domain of PAX6 is required for this function.
  • A significant reverse correlation (P < 0.05) occurred between PAX6 and MMP2 expression quantified by real-time quantitative RT-PCR in 41 GBMs, 43 anaplastic astrocytomas, and 7 adjacent normal tissues.
  • Interestingly, the degree and significance of the reverse correlation increased after excluding astrocytomas, whereas it became insignificant after excluding GBMs.
  • [MeSH-minor] Adenoviridae / genetics. Animals. Astrocytoma / enzymology. Astrocytoma / genetics. Astrocytoma / pathology. Cell Line, Tumor. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Nude. Neoplasm Invasiveness. Promoter Regions, Genetic. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047041.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR020146
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


45. Wacker A, Will BE, Schöning M, Neunhoeffer F: [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma]. Z Geburtshilfe Neonatol; 2008 Oct;212(5):194-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].
  • BACKGROUND: Anaplastic astrocytomas in neonates are extremely rare.
  • No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.
  • CONCLUSION: Congenital anaplastic astrocytomas have a variable outcome, with different survival rates as compared to adults.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956278.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Pavon LF, Marti LC, Sibov TT, Malheiros SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E, Gamarra LF: The ultrastructural study of tumorigenic cells using nanobiomarkers. Cancer Biother Radiopharm; 2010 Jun;25(3):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances, patients with malignant brain tumors still have a poor prognosis.
  • Glioblastoma (WHO grade 4 astrocytoma), the most malignant brain tumor, represents 50% of all astrocytomas, with a median survival rate of <1 year.
  • The process of tumor cell labeling using nanoparticles can successfully contribute to the identification of tumorigenic cells and consequently for better understanding of glioblastoma genesis and recurrence.
  • In addition, this method may help further studies in tumor imaging, diagnosis, and prognostic markers detection.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, CD29 / immunology. Antigens, CD29 / metabolism. Antigens, CD44 / immunology. Antigens, CD44 / metabolism. Biomarkers / analysis. Biomarkers / chemistry. Cell Line, Tumor. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Cytoplasmic Vesicles / metabolism. Endocytosis / immunology. Flow Cytometry. Forkhead Transcription Factors / chemistry. Forkhead Transcription Factors / metabolism. Glycoproteins / immunology. Glycoproteins / metabolism. Humans. Immunophenotyping. Magnetite Nanoparticles / chemistry. Microscopy, Electron, Transmission. Nanomedicine / methods. Peptides / immunology. Peptides / metabolism. Quantum Dots. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578834.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD29; 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44 protein, human; 0 / ENG protein, human; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Glycoproteins; 0 / Magnetite Nanoparticles; 0 / Peptides; 0 / Receptors, Cell Surface
  •  go-up   go-down


48. Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A: Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res; 2008 Apr;30(3):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.
  • It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood.
  • The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
  • METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation).
  • Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls.
  • Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / cerebrospinal fluid. Interleukin-10 / blood. Interleukin-10 / cerebrospinal fluid. Transforming Growth Factor beta2 / blood. Transforming Growth Factor beta2 / cerebrospinal fluid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848206.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta2; 130068-27-8 / Interleukin-10
  •  go-up   go-down


49. Cao WD, Zhang X, Zhang JN, Yang ZJ, Zhen HN, Cheng G, Li B, Gao D: Immunocytochemical detection of 14-3-3 in primary nervous system tumors. J Neurooncol; 2006 Apr;77(2):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, 14-3-3 immunoreactivity was seen in the majority of astrocytomas [grade I (9/11), II (16/21), III (13/17), IV (17/21)].
  • There was no difference between the positive expression rates of 14-3-3 in different grades of astrocytomas (P = 0.968).
  • But the intensity and degree of 14-3-3 immunoreactivity in diffuse astrocytomas, anaplastic astrocytoma, and glioblastoma multiformes showed trends with tumor grade, with glioblastomas having the highest positivity (P = 0.048).
  • The 14-3-3 immunoreactivity was also seen in the majority of other gliomas [oligodendroglioma (2/3), anaplastic oligodendroglioma (4/4), ependymoma (1/2), anaplastic ependymoma (2/2), choroid plexus papilloma (3/3), pineocytoma (2/2), medulloblastoma (5/8)].
  • The up-regulated expression of 14-3-3 may be a common mechanism for evading apoptosis in most primary human nervous system tumors, and targeting 14-3-3 may be a novel promising strategy for the treatment of these tumors, especially for malignant tumors.
  • [MeSH-major] 14-3-3 Proteins / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2004 Apr 15;379(Pt 2):395-408 [14744259.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):668-75 [12296652.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8511-5 [10411906.001]
  • [Cites] Pathol Res Pract. 2002;198(12):813-9 [12608658.001]
  • [Cites] Exp Cell Res. 2001 Nov 15;271(1):142-51 [11697890.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):767-74 [10079254.001]
  • [Cites] J Neurochem. 1982 May;38(5):1475-82 [7062063.001]
  • [Cites] Cell. 1996 Nov 15;87(4):619-28 [8929531.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Feb;5(1):177-91 [15757449.001]
  • [Cites] FEBS Lett. 1993 Oct 4;331(3):296-303 [8375512.001]
  • [Cites] EMBO J. 2000 Feb 1;19(3):349-58 [10654934.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10142-6 [7479742.001]
  • [Cites] J Neurochem. 1982 May;38(5):1466-74 [7038050.001]
  • [Cites] Acta Neuropathol. 2004 Feb;107(2):137-43 [14605832.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:617-47 [10836149.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):2058-65 [12426317.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1143-51 [11007952.001]
  • [Cites] FASEB J. 2003 Apr;17(6):767-9 [12594176.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11663-9 [9111084.001]
  • [Cites] Biochem Soc Trans. 2002 Aug;30(4):387-91 [12196100.001]
  • [Cites] Annu Rev Med. 1997;48:267-81 [9046961.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):245-53 [11895039.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Jul;34(7):429-35 [7526231.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Bioessays. 2001 Oct;23(10):936-46 [11598960.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):11-23 [12535517.001]
  • [Cites] Ann Neurol. 2002 Dec;52(6):722-31 [12447925.001]
  • [Cites] Biochem Soc Trans. 2002 Aug;30(4):360-5 [12196095.001]
  • [Cites] Trends Biochem Sci. 1992 Dec;17(12):498-501 [1471260.001]
  • (PMID = 16292484.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / YWHAB protein, human
  •  go-up   go-down


50. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS; 2006 Oct;114(10):731-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
  • The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported.
  • Postoperative irradiation and chemotherapy could not repress tumor progression; therefore, treatment was undertaken with an oncolytic virus, MTH-68/H, an attenuated strain of Newcastle disease virus (NDV), and valproic acid (VPA), an antiepileptic drug, which also has antineoplastic properties.
  • This treatment resulted in a far-reaching regression of the thalamic glioma, but 4 months later a new tumor manifestation, an extension of the thalamic tumor, appeared in the wall of the IVth ventricle, which required a second neurosurgical intervention.
  • Under continuous MTH-68/H - VPA administration the thalamic tumor remained under control, but the rhombencephalic one progressed relentlessly and led to the fatal outcome.
  • In the final stage, a third tumor manifestation appeared in the left temporal lobe.
  • The possible reasons for the antagonistic behavior of the three manifestations of the same type of glioma to the initially most successful therapy are discussed.
  • The comparative histological study of the thalamic and rhombencephalic tumor manifestations revealed that MTH-68/H treatment induces, similar to in vitro observations, a massive apoptotic tumor cell decline.
  • In the rhombencephalic tumor, in and around the declining tumor cells, NDV antigen could be demonstrated immunohistochemically, and virus particles have been found in the cytoplasm of tumor cells at electron microscopic investigation.
  • [MeSH-major] Anticonvulsants / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / therapy. Brain Neoplasms / therapy. Valproic Acid / therapeutic use. Viral Vaccines / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004977.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antigens, Viral; 0 / Newcastle disease virus vaccine MTH-68-H; 0 / Viral Vaccines; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


52. Chang CL: Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme. J Biomol Screen; 2008 Oct;13(9):912-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme.
  • The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ-synthesized 60-mer oligonucleotide microarray.
  • The signal intensity of each feature was measured by laser scanner, and gene expression was quantified as the tumor/NB intensity ratio.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Glioblastoma / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812569.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Oligonucleotides
  •  go-up   go-down


53. Ehling R, Sterlacci W, Maier H, Berger T: A 45-year old male with left-sided hemihypesthesia. Brain Pathol; 2010 Mar;20(2):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extensive immunological and radiological investigations were not able to differentiate between an intrinsic brain tumor and a demyelinating disease.
  • Stereotactic biopsies of the brainstem were performed; the findings of abundant Rosenthal fibers, interjacent spindle-shaped and gemistocytic cells partially with dark and irregularly formed nuclei favored primarily the diagnosis of a malignant astrocytoma, although a demyelinating disease could not be definitely excluded.

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438473.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


54. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterozygous point mutations of isocitrate dehydrogenase (IDH)1 codon 132 are frequent in grade II and III gliomas.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


55. Niizuma K, Fujimura M, Kumabe T, Tominaga T: Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome. J Clin Neurosci; 2007 Jan;14(1):53-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.
  • A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma.
  • The clinical course and histological findings suggest that the parasitic infection and/or genetic changes contributed to the malignant transformation of the astrocytic tumour.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Neurocysticercosis / pathology

  • Genetic Alliance. consumer health - Turcot syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138070.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


56. Doherty MJ, Hampson NB: Partial seizure provoked by hyperbaric oxygen therapy: possible mechanisms and implications. Epilepsia; 2005 Jun;46(6):974-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient after resection of anaplastic astrocytoma and 5,580 cGy of total external-beam radiation treatments with brain radiation necrosis who underwent HBO2 therapy and developed a partial seizure during treatment.
  • [MeSH-minor] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Combined Modality Therapy. Humans. Male. Middle Aged. Necrosis / etiology. Necrosis / pathology. Necrosis / therapy. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946345.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Larysz D, Blamek S, Larysz P, Pietras K, Mandera M: Posterior fossa brain tissue injury: developmental, neuropsychological, and neurological consequences of brain tumors in children. Acta Neurochir Suppl; 2010;106:271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was the functional neurodevelopmental assessment of children with posterior fossa tumors, specifically examining whether tumor location in particular cerebellar structures determines particular neuropsychological deficits.
  • There were 21 total and 8 subtotal resections of tumor, and marsupialization was performed in cases of arachnoid cysts.
  • Histopathological diagnoses of tumors were as follows: 4 medulloblastomas, 8 pilocytic astrocytomas, 6 fibrillary astrocytomas, 1 anaplastic astrocytoma, 2 oligodendrogliomas, 4 anaplastic ependymomas, 1 choroid plexus papilloma, and 5 arachnoid cysts.

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812963.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


58. Park SH, Min HS, Kim B, Myung J, Paek SH: Galectin-3: a useful biomarker for differential diagnosis of brain tumors. Neuropathology; 2008 Oct;28(5):497-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It showed consistent and diffuse positivity in 100% of the pilocytic astrocytomas, pleomorphic xanthoastrocytomas (PXA), Schwannomas, meningiomas, capillary hemangioblastomas, as well as in ependymomas, but it was completely negative in the diffuse astrocytomas, anaplastic astrocytomas, both low- and high-grades of the oligodendrogliomas, central neurocytomas, and medulloblastomas.
  • Definitely positive but heterogeneous expression was found in various tumors including subependymal giant cell astrocytomas (SEGA), classic glioblastoma multiforme, anaplastic oligoastrocytomas, CNS primitive neuroectodermal tumors (CNS PNETs), and hemangiopericytomas.
  • Focal positivity for gal-3 was also found in dysembryoplastic neuroepithelial tumors (DNTs) and gangliogliomas, in which the positive cells were the astrocytic component.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Galectin 3 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384511.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


59. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Risk Factors. Survival Analysis


60. Das A, Simmons C, Danielpour M: A congenital brain tumor associated with assisted in vitro fertilization. Case report. J Neurosurg; 2005 Nov;103(5 Suppl):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A congenital brain tumor associated with assisted in vitro fertilization. Case report.
  • In this report the authors describe the clinical features of a rare neonatal anaplastic astrocytoma in the setting of in vitro fertilization (IVF).
  • Grosstotal resection of an anaplastic astrocytoma was followed by chemotherapy with temozolomide and vincristine.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Fertilization in Vitro / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2007 May;106(5 Suppl):418; author reply 418-9 [17566216.001]
  • (PMID = 16302619.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


61. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS: Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol; 2008 Feb;10(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.
  • We describe the case of a patient with transcobalamin II deficiency, hypogammaglobulinemia, absent corpus callosum, and mental retardation who presented at an early age with colorectal cancer and multifocal anaplastic astrocytoma.
  • He was found to have a possible germline mutation of the PMS2 gene, as evidenced by absent protein expression in both normal and tumor tissues.
  • [MeSH-major] Abnormalities, Multiple / genetics. Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics


62. Hatori M, Hosaka M, Watanabe M, Moriya T, Sasano H, Kokubun S: Osteosarcoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Tohoku J Exp Med; 2006 Apr;208(4):343-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma in a patient with neurofibromatosis type 1: a case report and review of the literature.
  • Neurofibromatosis type 1 (NF1) or von Recklinghausen's disease is a genetic disease generally characterized by café-au-lait spots and neurofibromas.
  • Malignant tumors of the nervous system, such as malignant schwannomas, gliomas, or astrocytomas, have been well known to coexist with neurofibromatosis.
  • However, occurrence of malignant tumors unrelated to the nervous system is rare.
  • We report an unusual case of a 29-year-old NF1 female suffering from malignant peripheral nerve sheath tumor (MPNST) that eventually developed osteosarcoma in the proximal femur.
  • Osteosarcoma is the most common high-grade malignant bone tumor in which the neoplastic cells produce osteoid.
  • Magnetic resonance imaging revealed extraskeletal growth of the tumor.
  • The removed tumor was composed of highly anaplastic cells.
  • Lace-like irregular osteoid formation was observed among the tumor cells.
  • The tumor was diagnosed as osteoblastic type osteosarcoma.
  • The correlation between the histogenesis of osteosarcoma and the genetic abnormality in NF1 patients has not been elucidated, but the finding of osteosarcomatous transformation in this case suggests the divergent cellular differentiation to mesenchymal malignant tumors of neuroectodermal tissue in NF1 patients.


63. Roselli F, Pisciotta NM, Aniello MS, Niccoli-Asabella A, Defazio G, Livrea P, Rubini G: Brain F-18 Fluorocholine PET/CT for the assessment of optic pathway glioma in neurofibromatosis-1. Clin Nucl Med; 2010 Oct;35(10):838-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging, magnetic resonance spectroscopy (MRS), and F-18 fluorocholine revealed a splenial mass with imaging features compatible with malignant astrocytoma.


64. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • This promising activity warrants further investigation of this combination in larger phase II or III studies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


65. Schittenhelm J, Mittelbronn M, Nguyen TD, Meyermann R, Beschorner R: WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes. Brain Pathol; 2008 Jul;18(3):344-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes.
  • Particularly in small brain biopsies, it might be difficult to distinguish reactive astrogliosis from low-grade or infiltration zones of high-grade astrocytomas.
  • Recently, the over-expression of Wilms' tumor gene product WT1 was reported in astrocytic tumor cells.
  • Therefore, we investigated WT1 expression in paraffin-embedded brain sections from 28 controls, 48 cases with astrogliosis of various etiology and 219 astrocytomas [World Health Organization (WHO) grades I-IV] by immunohistochemistry.
  • In astrocytomas, WT1-positive tumor cells were found in pilocytic astrocytomas (66.7% of cases), diffuse astrocytomas (52.7%) WHO grade II (52.7%), anaplastic astrocytomas (83.4%) and glioblastomas (98.1%).
  • Overall, the majority of all astrocytic neoplasms (84.5%) expressed WT1.
  • Establishing a cut-off value of 0% immunoreactive tumor cells served to recognize neoplastic astrocytes with 100% specificity and 68% sensitivity and was associated with positive and negative predictive values of 1 and 0.68, respectively.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gliosis / metabolism. WT1 Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Endothelial Cells / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371184.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


66. Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y, Frei K: Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol; 2008 May;67(5):435-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occludin, claudin 1, and claudin 5 were expressed in microvascular endothelial cells in nonneoplastic brain samples but were significantly reduced in anaplastic astrocytoma and glioblastoma samples.
  • [MeSH-minor] Brain / blood supply. Brain / pathology. Brain / physiopathology. Brain Edema / metabolism. Brain Edema / pathology. Brain Edema / physiopathology. Cells, Cultured. Cerebral Arteries / metabolism. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Claudin-1. Claudin-5. Coculture Techniques. Down-Regulation / physiology. Extracellular Matrix / metabolism. Extracellular Matrix / pathology. Humans. Infant, Newborn. Membrane Proteins / metabolism. Occludin. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431253.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-5; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin; 0 / Transforming Growth Factor beta2; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


67. Benesch M, Wagner S, Berthold F, Wolff JE: Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol; 2005 Apr;72(2):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
  • PURPOSE: Clinical data on central nervous system (CNS) dissemination of high-grade gliomas (HGG) at initial presentation in children are rare.
  • Data concerning tumor dissemination are available from 324 patients.
  • RESULTS: A total of 10 patients (3.1%) (anaplastic astrocytoma: n=3, glioblastoma multiforme: n=6, diffuse intrinsic pontine glioma: n=1) had primary tumor dissemination.
  • The most frequent primary tumor sites were the cortex (n=4), followed by the ventricles (n=2), cerebellum (n=1), spinal cord (n=1), and pons (n=1).
  • Median progression-free and overall survival was 0.8 years (95% CI 0.2-1.4) and 1.5 years (95% CI 0.67-2.29) for patients with primary tumor dissemination, respectively, with no statistically significant differences between the group with and the group without primary tumor dissemination.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Neoplasm Invasiveness. Radiotherapy. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):355-64 [2823687.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurology. 1991 Jan;41(1):46-50 [1985295.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):64-71 [1738457.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Ann Neurol. 1985 Aug;18(2):217-21 [4037762.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Ann Neurol. 1983 Aug;14(2):177-82 [6625534.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):945-9 [12434281.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1347-53 [10506724.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):239-47 [14558599.001]
  • (PMID = 15925999.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide
  •  go-up   go-down


68. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer; 2005 Jan 15;103(2):329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
  • BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease.
  • METHODS: Patients with MG at any type of recurrence received CPT-11, administered as a 90-minute intravenous infusion on Weeks 1, 2, 4, and 5 of each 6-week cycle plus celecoxib, which was administered continuously at a dose of 400 mg twice a day.
  • RESULTS: Thirty-four of the 37 patients enrolled in the current study (92%) were diagnosed with recurrent GBM and 3 patients (8%) were diagnosed with recurrent anaplastic astrocytoma (AA).
  • Hematologic toxicities of >/= Grade 3 (according the second version of the Common Toxicity Criteria of the National Cancer Institute) reportedly complicated 8.6% of treatment courses.
  • Grade 3 diarrhea, the most commonly reported nonhematologic toxicity, occurred with equal frequency (8%), regardless of whether the patient was receiving EIAED.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Adult. Aged. Biological Availability. Celecoxib. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15558802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 7673326042 / irinotecan; JCX84Q7J1L / Celecoxib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


69. Kawarabuki K, Ohta T, Hashimoto N, Wada K, Maruno M, Yamaki T, Ueda S: Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol; 2005 Mar-Apr;24(2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present case, tumor lesions were observed in each cerebellar hemisphere.
  • The left-side lesion was diagnosed as glioblastoma, and the right-side lesion as malignant astrocytoma by histopathology.
  • Immunohistochemistry revealed that the tumor cells of the left-side lesion was positive for p53, whereas epidermal growth factor receptors (EGFR) were negative in tumor cells from both sides.
  • Genetic alterations were investigated using a genome DNA microarray (GenoSensor Array 300), which has led us to define this tumor as a secondary glioblastoma.


70. Nakamura M, Shimada K, Nakase H, Konishi N: [Clinicopathological diagnosis of gliomas by genotype analysis]. Brain Nerve; 2009 Jul;61(7):773-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastomas (WHO grade IV) may develop de novo (primary glioblastomas) or through progression from lower-grade astrocytomas (secondary glioblastomas) both glioblastomas show similar histological features.
  • However, the histological differentiation of oligodendrogliomas from diffuse astrocytoma could be highly subjective in cases without typical morphological features.
  • Loss of heterozygosity (LOH) on chromosomes 1p and 19q is correlated with sensitivity to PCV chemotherapy with increased survival in anaplastic oligodendroglioma cases (WHO grade III).
  • We have previously found methylation or expression mosaicism of O6-MGMT in gliomas, resulting in problems on tumor sampling and response to TMZ.
  • This article suggests that more biological and molecular approaches to brain tumor classification will provide improved means to treat these tumors.
  • [MeSH-minor] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Humans. Lomustine / administration & dosage. Loss of Heterozygosity. Pharmacogenetics. Procarbazine / administration & dosage. Prognosis. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618854.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  • [Number-of-references] 42
  •  go-up   go-down


71. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C: Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ; 2010 May;17(5):833-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family of cytokines, causes apoptosis by caspase activation in various cell types, particularly in transformed cells.
  • We report here a new signal transduction pathway involving protein kinase Cdelta (PKCdelta), NADPH oxidase 4 (NOX4) and reactive oxygen species (ROS), that inhibits caspase-dependent cell death induced by TRAIL ligation in human malignant astrocytoma cells.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / metabolism. Caspase 3 / metabolism. Reactive Oxygen Species / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Humans. Immunoblotting. NADPH Oxidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876066.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.6.3.- / NOX4 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


72. Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA: Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed; 2007 Dec;20(8):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 145 histologically diagnosed brain tumour spectra were acquired [14 astrocytoma grade II (AS2), 15 astrocytoma grade III (AS3), 42 glioblastoma (GBM), 41 metastases (MET) and 33 meningioma (MNG)], and linear discriminant analyses (LDA) were performed on the LCModel analysis of the spectra and the original spectra.
  • LDA of AS2, MNG and high-grade tumours (HG, comprising GBM and MET) correctly classified 94% using the LCModel dataset compared with 93% using the spectral dataset.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326043.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Arjona D, Bello MJ, Alonso ME, Isla A, De Campos JM, Vaquero J, Sarasa JL, Gutierrez M, Rey JA: Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas. Diagn Mol Pathol; 2005 Dec;14(4):224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas.
  • We have studied gene amplification of genes located in 1q32 (GAC1, ELF3, MDM4, and ren1), 4q11 (PDGFR-alpha), and in 12q13-14 (MDM2 and CDK4) using quantitative real-time PCR in a group of 86 tumors consisting of 44 WHO grade IV glioblastomas (GBM) (34 primary and 10 secondary tumors), 21 WHO grade III anaplastic astrocytomas (AA), and 21 WHO grade II astrocytomas (AII).
  • GAC1 (51%) and MDM4 (27%) were the most frequently amplified genes within the 1q32 amplicon, and their higher amplification frequency was statistically significant (P<0.05, chi) in the low-grade astrocytomas.
  • Concordant co-amplification was determined for ELF3 and ren1 or ren1 and MDM4 in the grade III-IV tumors.
  • The present study shows that gene amplification in the studied regions is already present in low-grade astrocytic tumors and that amplification of some genes may represent another molecular marker to differentiate primary from secondary GBM.
  • [MeSH-major] Astrocytoma / genetics. Gene Amplification. Gene Dosage. Proto-Oncogenes / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319692.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y: Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol; 2005 Mar;109(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DcR3 has been demonstrated to produce a secreted member of the tumor necrosis factor receptor superfamily that negatively regulates Fas-mediated apoptosis.
  • In this study we examined DcR3 gene amplification, DcR3 mRNA expression, and DcR3 protein expression in 46 human astrocytic brain tumors by quantitative genomic PCR, quantitative reverse transcription-PCR, and immunohistochemistry, respectively.
  • The DcR3 gene amplification was detected in none of 6 (0%) low-grade astrocytomas, 1 of 16 (6%) anaplastic astrocytomas, and 6 of 24 ( 25%) glioblastomas.
  • We thus concluded that high DcR3 mRNA expression and protein expression may be positively related to the gene amplification in astrocytic brain tumors, especially glioblastomas.
  • Further, we speculated that the DcR3 gene amplification with overexpression may be responsible for malignant features in glioblastomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptors, Tumor Necrosis Factor. Receptors, Tumor Necrosis Factor, Member 6b. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627206.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


75. Hunter SB, Varma V, Shehata B, Nolen JD, Cohen C, Olson JJ, Ou CY: Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem; 2005 Aug;53(8):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apolipoprotein D (apoD) expression has been shown to correlate both with cell cycle arrest and with prognosis in several types of malignancy, including central nervous system astrocytomas and medulloblastomas.
  • Sixteen poorly infiltrating WHO grade I glial neoplasms (i.e., pilocytic astrocytomas and gangliogliomas) showed an average 20-fold higher apoD expression level compared with the 20 diffusely infiltrating glial neoplasms (i.e., glioblastoma, anaplastic astrocytoma, oligodendrogliomas; p=0.00004).
  • Analyzed as individual tumor groups, poorly infiltrating grade I pilocytic astrocytomas and gangliogliomas differed significantly from each tumor type within the diffusely infiltrating higher-grade category (p<0.05 for each comparison) but not from each other (p>0.05).
  • Conversely, each individual tumor type within the diffusely infiltrating category differed significantly from both pilocytic astrocytomas and gangliogliomas (p<0.05) but did not vary from other infiltrating tumors (p>0.05).
  • Ependymomas, non-infiltrating grade II neoplasms, expressed levels of apoD similar to or lower than levels expressed by the diffusely infiltrating gliomas.
  • In addition, apoD expression was 5-fold higher in the slowly proliferating grade I glial neoplasms compared with non-proliferating normal brain tissue (p=0.01), suggesting that apoD expression is not simply an inverse measure of proliferation.
  • ApoD expression measured by quantitative RT-PCR may be useful in the differential diagnosis of primary brain tumors, particularly pilocytic astrocytomas and gangliogliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055749.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Fixatives; 0 / Ki-67 Antigen; 1HG84L3525 / Formaldehyde; 8002-74-2 / Paraffin
  •  go-up   go-down


76. Johannessen AL, Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res; 2006;12(3):143-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
  • The current WHO classification of human astrocytomas has limitations in predicting prognosis and diagnosis, and there is a need for additional factors.
  • All studies show increasing values of Ki-67/MIB-1 LI with increasing grade of malignancy.
  • Most of them demonstrate that MIB-1 LI differentiates well between diffuse astrocytomas WHO grade II (AII) and anaplastic astrocytomas (AA) and between AII and glioblastomas (GM), but not between AA and GM.
  • The studies reviewed report MIB-1 LI as an important prognostic factor in human astrocytomas.
  • Due to the great spread of values between the various tumor grades, however, MIB-1 LI cannot be used as a diagnostic factor alone but should be used in combination with established criteria of histological malignancy.
  • It may be especially useful in cases where histology reveals a low-grade astrocytoma whereas other parameters indicate a more malignant neoplasm.
  • Thus, it is our opinion that MIB-1 LI should be a part of the routine investigation in patients with astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ki-67 Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2004 Nov-Dec;23(6):262-70 [15584210.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):931-6 [9786243.001]
  • [Cites] Clin Neuropathol. 2002 Nov-Dec;21(6):252-7 [12489673.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):31-5 [9210051.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Dec;16(4):389-94 [9505211.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):857-65 [9258255.001]
  • [Cites] Pathol Res Pract. 2002;198(4):261-5 [12049334.001]
  • [Cites] Cancer. 1997 Dec 1;80(11):2133-40 [9392336.001]
  • [Cites] Pathol Oncol Res. 2001;7(4):267-78 [11882906.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):724-9 [9574635.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):25-30 [9757314.001]
  • [Cites] Lab Invest. 1993 Jun;68(6):629-36 [7685843.001]
  • [Cites] Acta Neuropathol. 1994;87(1):47-54 [7511316.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):798-805 [9210876.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • (PMID = 16998593.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  • [Number-of-references] 20
  •  go-up   go-down


77. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol; 2010 Oct;66(5):927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma.
  • 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2-5)).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):581-6 [9773800.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):285-9 [10359149.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Eur J Pharmacol. 2001 Jan 19;412(1):21-5 [11166732.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] Onkologie. 1983 Apr;6(2):58-61 [6223253.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):382-8 [3417367.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):382-3 [2407368.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4837-44 [1893376.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90 [8384328.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1696-9 [7691116.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(2):215-20 [8686548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309-15 [8738036.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):587-90; discussion 590-1 [8837815.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):161-7 [9266454.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-52-S12-55 [9331122.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):307-16 [9488600.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • (PMID = 20107803.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572-26; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS335377; NLM/ PMC3265324
  •  go-up   go-down


78. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brännström T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol; 2006 Jul;78(3):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
  • Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma.
  • The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV.
  • For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
  • In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
  • Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
  • In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
  • Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
  • In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Estramustine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1713-6 [2697186.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):360-6 [8832674.001]
  • [Cites] Br J Cancer. 1988 Sep;58(3):326-9 [3052561.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Prostate. 1989;14(1):27-43 [2648345.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):693-6 [2369085.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):215-20 [15072470.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1111-7 [11181676.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):962-4 [1709687.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):358-61 [8431366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):142-8 [10389990.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1254-9 [10715295.001]
  • [Cites] J Neurooncol. 1994;22(2):111-26 [7745464.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):717-20 [7710934.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):87-91 [9516956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):555-7 [8005815.001]
  • [Cites] Clin Pharmacokinet. 1998 Feb;34(2):163-72 [9515186.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1415-7 [8137240.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):422-30; discussion 430-1 [8384327.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2079-84 [9748122.001]
  • [Cites] J Neurooncol. 1995;23(3):191-200 [7673981.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4974-9 [8069865.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • (PMID = 16598426.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35LT29625A / Estramustine
  •  go-up   go-down


79. Wang M, Tang J, Liu S, Yoshida D, Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol; 2005 Jan;71(1):3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.
  • Samples were taken from supratentorial gliomas border and normal brain autopsy which were divided into four groups, these including eight cases normal brain tissues, 30 cases of astrocytomas, 25 cases of anaplastic astrocytomas and 22 cases of glioblastomas.
  • Only 9 out of 30 cases of astrocytomas showed a low percentage of positive cells that were stained in a light, diffuse cytoplasmic pattern (score +).
  • Twenty-two out of 35 cases of anaplastic astrocytomas showed positive light, granular staining pattern, it including five samples (score +), and 17 samples (score + +).
  • Positive staining tumor cells were found in extracellular matrix (ECM), basement membrane (BM), and the endothelial cells of blood vessels were also positive stained.
  • Along with elevating glioma grade, CB expression and MVD value were both increased.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / enzymology. Cathepsin B / metabolism. Supratentorial Neoplasms / blood supply. Supratentorial Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Glioblastoma / blood supply. Glioblastoma / enzymology. Glioblastoma / pathology. Humans. Immunohistochemistry. In Vitro Techniques. Male. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22 [1515091.001]
  • [Cites] Biochem J. 1992 Feb 15;282 ( Pt 1):273-8 [1540143.001]
  • [Cites] Anat Rec. 1998 Oct;252(2):281-9 [9776083.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] J Neurooncol. 2002 May;58(1):21-32 [12160137.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):680-6 [10374777.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):510-9 [10507778.001]
  • [Cites] Eur J Biochem. 2000 Jul;267(13):4165-70 [10866820.001]
  • [Cites] FEBS Lett. 1999 Jul 23;455(3):286-90 [10437790.001]
  • [Cites] Cancer Gene Ther. 2003 Feb;10(2):141-51 [12536203.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1121-42 [1700617.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):578-86; discussion 586-8 [11841727.001]
  • [Cites] Biochim Biophys Acta. 1993 Jul 28;1178(1):55-62 [8329457.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Clin Exp Metastasis. 1992 May;10(3):145-55 [1582084.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):187-96; discussion 196-7 [12493117.001]
  • [Cites] J Pathol. 1997 Jun;182(2):205-10 [9274532.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4870-5 [2758418.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12806-12 [10777578.001]
  • [Cites] Surg Today. 2001;31(5):385-9 [11381499.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):125-30 [9524063.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):483-94 [10571410.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):519-24 [11494030.001]
  • [Cites] Brain Pathol. 1994 Apr;4(2):157-66 [7520326.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1013-21 [9508185.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4747-53 [9494601.001]
  • (PMID = 15719267.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


80. Meije Y, Lizasoain M, García-Reyne A, Martínez P, Rodríguez V, López-Medrano F, Juan RS, Lalueza A, Aguado JM: Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis; 2010 Jun 15;50(12):e73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma.

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455691.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 16
  •  go-up   go-down


81. Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol; 2010;5:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
  • The aim of this study was to investigate EGFR gene amplification and expression of c-erbB1-4 receptor proteins in human anaplastic astrocytomas.
  • This study shows the convenience and feasibility of immunohistochemistry when determining the expression of receptor proteins in tissue sections of human astrocytomas.
  • The synchronous overexpression of c-erbB1-4 proteins in anaplastic astrocytomas supports their role in the pathogenesis of these tumors.
  • [MeSH-major] Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Receptor, ErbB-2 / analysis. Supratentorial Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal. Biopsy. Feasibility Studies. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-4. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):338-48 [17975007.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):281-7 [17571214.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23 [18454306.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):259-68 [18454307.001]
  • [Cites] Curr Treat Options Oncol. 2008 Feb;9(1):23-31 [18247132.001]
  • [Cites] Exp Cell Res. 2008 Oct 1;314(16):2907-18 [18687326.001]
  • [Cites] Minim Invasive Neurosurg. 2009 Feb;52(1):17-24 [19247900.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 May;17(3):220-6 [19391220.001]
  • [Cites] J Natl Cancer Inst. 2009 May 20;101(10):736-50 [19436038.001]
  • [Cites] Brain Pathol. 2009 Oct;19(4):713-23 [19744042.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1593-611 [11920518.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(2):113-37; discussion 137-8 [10795886.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):83-96 [11397666.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]
  • [Cites] Cell. 2002 Sep 20;110(6):669-72 [12297041.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e1-13 [12456322.001]
  • [Cites] Brain Pathol. 2003 Jan;13(1):52-61 [12580545.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):332-5 [12902879.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] Diagn Mol Pathol. 2004 Mar;13(1):1-8 [15163002.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(2):147-55 [2563600.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1716-20 [1671042.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(1):61-4 [2021959.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Jan;51(1):84-90 [1311022.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):295-301 [1320666.001]
  • [Cites] Acta Neurochir (Wien). 1992;117(3-4):182-6 [1414519.001]
  • [Cites] Eur J Cancer. 1993;29A(11):1604-6 [8105841.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):72-7 [8262681.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):772-80 [7914508.001]
  • [Cites] J Neurooncol. 1994;22(3):201-7 [7760096.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):169-74 [7671460.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):179-93; discussion 193-4 [7477768.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):620-3 [8605096.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1047-53 [8644846.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):215-22 [9516974.001]
  • [Cites] J Pathol. 1998 Jul;185(3):236-45 [9771476.001]
  • [Cites] Brain Pathol. 1998 Oct;8(4):655-67 [9804374.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Dec;57(12):1138-45 [9862636.001]
  • [Cites] Cancer Invest. 2004;22(4):537-44 [15565811.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):89-92 [15943037.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27 [16113093.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):91-6 [16540738.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):74-89 [16488082.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Aug;32(4):441-50 [16866989.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):56-8 [17536308.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):353-9 [17987795.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):271-3 [17981994.001]
  • (PMID = 20331873.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-4
  • [Other-IDs] NLM/ PMC2859381
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


82. Higgins SC, Pilkington GJ: The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res; 2010 Feb;30(2):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma.
  • BACKGROUND: In this investigation the effects of tricyclic drugs on cellular respiration were studied using the anaplastic astrocytoma cell line IPSB-18 by use of a Clark-type oxygen electrode which measured changes in cellular respiration rate (oxygen consumption), in a dose-response assay.
  • [MeSH-major] Antidepressive Agents, Tricyclic / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Respiration / drug effects. Dexamethasone / pharmacology
  • [MeSH-minor] Amitriptyline / pharmacology. Antineoplastic Combined Chemotherapy Protocols. Clomipramine / pharmacology. Doxepin / pharmacology. Humans. Oxygen Consumption / drug effects. Respiratory Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXEPIN .
  • Hazardous Substances Data Bank. Clomipramine .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332444.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Antineoplastic Agents, Hormonal; 1668-19-5 / Doxepin; 1806D8D52K / Amitriptyline; 7S5I7G3JQL / Dexamethasone; NUV44L116D / Clomipramine
  •  go-up   go-down


83. Seo HS, Kim JH, Lee DH, Lee YH, Suh SI, Kim SY, Na DG: Nonenhancing intramedullary astrocytomas and other MR imaging features: a retrospective study and systematic review. AJNR Am J Neuroradiol; 2010 Mar;31(3):498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonenhancing intramedullary astrocytomas and other MR imaging features: a retrospective study and systematic review.
  • BACKGROUND AND PURPOSE: Most intramedullary astrocytomas have been known to exhibit at least some enhancement on MR imaging regardless of cell type or tumor grade.
  • The purpose of this study was to evaluate the incidence of nonenhancing intramedullary astrocytomas through a retrospective study within our institutions and a systematic review of the medical literature.
  • MATERIALS AND METHODS: A total of 19 consecutive patients (male to female ratio, 11:8; mean age, 27.84 +/- 19.0 years) with primary intramedullary astrocytomas (3 WHO grade I, 13 WHO grade II, 3 WHO grade III) who underwent preoperative MR imaging with contrast enhancement were included in this retrospective study from 4 institutions.
  • The tumor-enhancement patterns were classified into the following categories:.
  • Seven articles including MR imaging enhancement studies of intramedullary astrocytomas were eligible for literature review.
  • RESULTS: In the retrospective study, 6 astrocytomas (32%), including 2 anaplastic astrocytomas, did not enhance at all.
  • Focal nodular enhancement was identified in 5 astrocytomas (26%); patchy enhancement, in 3 (16%); inhomogeneous diffuse enhancement, in 5 (26%); and homogeneous diffuse enhancement, in none.
  • In the literature review, the frequency of nonenhancing intramedullary astrocytomas was 14 of 76 (18%), including 2 anaplastic astrocytomas.
  • CONCLUSIONS: Nonenhancing intramedullary astrocytomas are not uncommon and comprise between 20% and 30% of intramedullary astrocytomas.
  • Therefore, astrocytoma must remain in the differential diagnosis of nonenhancing intramedullary lesions, particularly if the lesion demonstrates a prominent mass effect or cord expansion.
  • [MeSH-major] Astrocytoma / pathology. Magnetic Resonance Imaging / methods. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875469.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 21
  •  go-up   go-down


84. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • This is in contrast to one study from West Bengal, India, in which only 7.9% of the brain tumors were GBMs, while 46.8% were astrocytomas.
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • Common to these approaches is the use of adjuvant radiation therapy, even as surgery alone, with or without chemotherapy, may be the mainstay for some lower grade and low-risk gliomas.
  • Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / therapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


85. Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, Jang SJ, Lee CH, Choi JR: Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci; 2009;39(4):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases included anaplastic astrocytoma (4 cases), anaplastic oligodendroglioma (2 cases), low grade astrocytoma (2 cases), low grade oligodendroglioma (1 case), and one case of secondary Philadelphia-positive acute lymphoblastic leukemia in a patient with glioblastoma multiforme.


86. Quant EC, Drappatz J, Wen PY, Norden AD: Recurrent high-grade glioma. Curr Treat Options Neurol; 2010 Jul;12(4):321-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent high-grade glioma.
  • OPINION STATEMENT: Opinions vary on the best treatment options for recurrent high-grade glioma.
  • Age, performance status, histology, tumor size and location, O6-methylguanine-DNA methyltransferase (MGMT) methylation status for glioblastoma, 1p/19q status for oligodendroglial tumors, and the number and types of prior therapies are important considerations.
  • Enrollment in a clinical trial is the optimal choice for most patients with recurrent high-grade glioma after failure of radiation therapy and temozolomide.
  • Involved-field external beam radiation should be considered for patients with anaplastic gliomas who have not received radiation.
  • For patients with anaplastic astrocytoma who progress after radiotherapy, temozolomide may be used.
  • For patients with anaplastic oligodendroglioma who progress after radiotherapy, PCV chemotherapy and temozolomide are options.
  • In the past, carmustine was commonly used to treat recurrent high-grade glioma, but the utility of carmustine in the modern era is unknown because most studies were performed prior to the widespread use of temozolomide.
  • High-precision re-irradiation such as stereotactic radiosurgery is another option in high-grade glioma, especially for patients with poor bone marrow reserve or inability to tolerate chemotherapy, but there is a paucity of studies with adequate controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 10;23 (23 ):5294-304 [15998902.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):550-5 [19332770.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Surg Neurol. 2008 May;69(5):506-9; discussion 509 [18262245.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] BMC Cancer. 2007 Aug 30;7:167 [17760992.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):167-73 [8145061.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2905-8 [19451418.001]
  • [Cites] Ther Clin Risk Manag. 2007 Oct;3(5):707-15 [18472995.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Mol Cells. 2009 Jul 31;28(1):7-12 [19655094.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):81-3 [16944309.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55 [19543728.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 [18037587.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):300-5 [18525311.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Lancet Neurol. 2008 Dec;7(12):1152-60 [19007739.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 [18272557.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1141-71, x [17964029.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20842591.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • BACKGROUND: We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • The median time to tumor progression was 7.2 months (range, 0-88.7 months) and median survival time was 13.3 months (range, 1.7-88.7 months).
  • This combined modality treatment program was associated with reversible grade 3 to 4 hematological toxicity in 10 patients, with grade 3 ototoxicity in one patient and grade 2 neurotoxicity in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


88. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg; 2007 Apr;106(4):575-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases.
  • OBJECT: The purpose of this retrospective study was to estimate the prognostic impact of treatment parameters for 170 patients with anaplastic astrocytoma (AA).
  • Resection of as much of the tumor as possible and delivery of a total radiation dose of greater than 60 Gy seem to be required for local control of AA.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432706.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia; 2005 Aug;7(8):717-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate in the current study that the EphA2 protein is restrictedly expressed in primary glioblastoma multiforme and anaplastic astrocytoma tissues in comparison to normal brain tissues.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):59-68 [12650608.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4481-9 [12907621.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8476-80 [14679012.001]
  • [Cites] J Clin Invest. 2004 Feb;113(3):425-33 [14755339.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] J Neurosurg. 1981 Jul;55(1):32-42 [6165811.001]
  • [Cites] J Exp Med. 1997 Jun 16;185(12):2043-51 [9182675.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):226-31 [15671550.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • (PMID = 16207473.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ PMC1501889
  •  go-up   go-down


90. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas.
  • The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
  • PATIENTS AND METHODS: In a phase II trial, 60 patients with recurrent malignant astrocytomas were treated with bevacizumab and irinotecan.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • CONCLUSION: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


91. Wykosky J, Gibo DM, Stanton C, Debinski W: Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res; 2008 Jan 1;14(1):199-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.
  • PURPOSE: We investigated the expression of interleukin-13 receptor alpha2 (IL-13R alpha 2), EphA2, and Fos-related antigen 1 (Fra-1) in astrocytomas and normal brain.
  • We sought to document whether the expression of the three factors changed with progression to higher grade malignancy and whether two or three targets in combination might be sufficient to target all patients with high-grade astrocytomas.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was done for IL-13R alpha 2, EphA2, and Fra-1 using human brain tumor tissue microarrays containing 30 specimens of WHO grades II and III astrocytomas, 46 glioblastoma multiformes (GBM), and 9 normal brain samples.
  • Western blotting was done for all three markers using GBM tumor specimens and xenograft cell lines.
  • RESULTS: Expression of all three proteins was significantly higher in GBM compared with normal brain, low-grade, and anaplastic astrocytomas.
  • CONCLUSIONS: IL-13R alpha 2, EphA2, and Fra-1 are attractive therapeutic targets representing molecular denominators of high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Interleukin-13 Receptor alpha2 Subunit / biosynthesis. Proto-Oncogene Proteins c-fos / biosynthesis. Receptor, EphA2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172271.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1F31 NS055533-01; United States / NCI NIH HHS / CA / R01 CA74145
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / Biomarkers, Tumor; 0 / Exotoxins; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Proto-Oncogene Proteins c-fos; 0 / Virulence Factors; 0 / fos-related antigen 1; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


92. Nagatani M, Ando R, Yamakawa S, Saito T, Tamura K: Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis. Toxicol Pathol; 2009 Aug;37(5):599-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis.
  • Among spontaneous neoplasms of the rat central nervous system, the discrimination between astrocytoma and malignant reticulosis (MR) is sometimes difficult because of their similar cell morphology and infiltration patterns.
  • These cases were diagnosed as benign/malignant astrocytoma containing no neoplastic oligodendroglial elements or MR according to the diagnostic criteria of the World Health Organization International Classification of Rodent Tumors (Mohr et al. 1994).
  • Astrocytomas were divided into three types and MR into two types based on the number of lesions, cellularity and infiltration patterns, and so on.
  • None of the tumor types showed any reactivity for GFAP or S-100 protein.
  • From the results of morphological and immunohistochemical examinations, it was indicated that there are no distinctive differences between spontaneous astrocytomas and MR in rats, and they are probably derived from the same cell lineage, that is, microglia, macrophage, or radial glia.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Central Nervous System Neoplasms / metabolism. Central Nervous System Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487256.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Vimentin
  •  go-up   go-down


93. Ooba H, Abe T, Kamida T, Anan M, Momii Y, Tokuuye K, Fujiki M: Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1641-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • To our knowledge, malignant fibrous histiocytosis caused by proton therapy has not been reported, therefore the clinical features of this complication are described and previous cases are reviewed.
  • [MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766005.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


94. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci; 2009 Oct;100(10):1996-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the genomic region spanning wild-type R132 of IDH1 by direct sequencing in 125 glial tumors.
  • In the present study, R172 mutation of the IDH2 gene was detected in one anaplastic astrocytoma.
  • IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%).
  • Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas.
  • Our data suggest that IDH1 or IDH2 mutation plays a role in early tumor progression of several types of glioma and might arise from a common glial precursor.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioma / genetics. Isocitrate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19765000.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


95. Dresemann G: Temozolomide in malignant glioma. Onco Targets Ther; 2010;3:139-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in malignant glioma.
  • Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and the most frequent primary tumor of the central nervous system.
  • Primary resection that is as complete as possible is recommended for malignant glioma.
  • For temozolomide naive GBM and astrocytoma grade III patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies.
  • The role of lower dosed, dose-dense, or continuous regimen with or without drug combination and the role of temozolomide for newly diagnosed astrocytoma grade III and low grade glioma still has to be determined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856849.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2939767
  • [Keywords] NOTNLM ; astrocytoma WHO grade III / glioblastoma multiforme / malignant glioma / temozolomide
  •  go-up   go-down


96. Vidiri A, Carapella CM, Pace A, Mirri A, Fabi A, Carosi M, Giannarelli D, Pompili A, Jandolo B, Occhipinti E, Di Giovanni S, Crecco M: Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. J Exp Clin Cancer Res; 2006 Jun;25(2):177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas.
  • Forty-seven patients with Glioblastoma (42) and Anaplastic Astrocytoma (5) were studied with MR 24 hrs after surgery.
  • In order to evaluate the role of early MR in defining the extent of surgical resection and its relation with the prognosis of malignant glioma patients, three categories of surgical resection were considered: gross total, sub-total and partial resection.
  • The study confirms that early-MR has to be considered an accurate technique for monitoring the extension of malignant glioma surgical resection and shows a good correlation between early-MR findings, PFS and ST.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918127.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


97. Hong X, Nelson KK, deCarvalho AC, Kalkanis SN: Heparanase expression of glioma in human and animal models. J Neurosurg; 2010 Aug;113(2):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Mammalian heparanase has been shown to function in tumor progression, invasion, and angiogenesis.
  • Heparanase expression in murine astrocytoma and human primary neurosphere animal models was examined using IHC.
  • RESULTS: The authors found that heparanase mRNA is greatly increased in gliomas including oligodendroglioma (9 samples), anaplastic astrocytoma (11 samples), and GBM (13 samples) as compared with healthy brain mRNA (3 samples).
  • Note, however, that no significant difference was observed among the 3 tumor groups.
  • Increased heparanase expression was also found in tumor tissues on Western blotting.
  • Heparanase-expressing cells, including GBM tumor cells and neovessel endothelial cells, exhibited decreased expression of CD44, a cell adhesion molecule on the cell membrane that is important for regulating tumor invasion.
  • In addition, heparanase-expressing tumor cells showed an elevated density of the cell proliferation marker Ki 67, as compared with its density in non-heparanase-expressing tumor cells, suggesting that heparanase expression is correlated with enhanced tumor proliferation.
  • Both murine astrocytoma cells (Ast11.9-2) and cultured primary human GBM neurospheres expressed heparanase when grown in animal brain tissue.
  • Multiple cell types contribute to the expression of heparanase, including neovessel endothelial cells, tumor cells, and infiltrated neutrophils.
  • [MeSH-minor] Animals. Antigens, CD44 / genetics. Antigens, CD44 / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / physiopathology. Blotting, Western. Disease Models, Animal. Endothelial Cells / physiology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Mice. Mice, Inbred C57BL. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / physiopathology. RNA, Messenger / metabolism. Rats. Rats, Nude. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835469.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / RNA, Messenger; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


98. Choi K, Choi C: Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways. Cancer Res Treat; 2009 Mar;41(1):36-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways.
  • PURPOSE: Malignant astrocytomas are among the commonest primary brain tumors and they have a grave prognosis, and so there is an urgent need to develop effective treatment.
  • In this study, we investigated the molecular mechanisms that are responsible for the anti-tumor effect of ginsenosides on human astrocytoma cells.
  • MATERIALS AND METHODS: We tested 13 different ginsenosides for their anti-tumor effect on human malignant astrocytoma cells in conjunction with Fas stimulation.
  • RESULTS: Among the 13 different ginsenoside metabolites, compound K and Rh(2) induced apoptotic cell death of the astrocytoma cells in a caspase- and p38 MAPK-dependent manner, yet the same treatment had no cytotoxic effect on the primary cultured human astrocytes.
  • CONCLUSION: These results suggest that ginsenoside metabolites in combination with Fas ligand may provide a new strategy to treat malignant astrocytomas, which are tumors that are quite resistant to conventional anti-cancer treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2006 Jun;91(2):356-64 [16547074.001]
  • [Cites] Planta Med. 2006 Jun;72(7):627-33 [16673329.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):1889-95 [9973455.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):216-25 [8617197.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Biochem Int. 1992 Jul;27(3):501-10 [1417886.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):167-76 [15072464.001]
  • [Cites] Cancer Lett. 2004 Mar 8;205(1):23-9 [15036657.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jan;44(1):65-81 [14739003.001]
  • [Cites] Mol Carcinog. 2004 Jan;39(1):1-9 [14694442.001]
  • [Cites] Free Radic Biol Med. 2003 Sep 15;35(6):648-61 [12957657.001]
  • [Cites] Blood. 2003 Jul 1;102(1):336-43 [12623840.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21446-52 [11934900.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):724-36 [11784850.001]
  • [Cites] J Korean Med Sci. 2001 Dec;16 Suppl:S38-41 [11748375.001]
  • [Cites] Cancer Lett. 2007 Nov 8;257(1):79-86 [17692455.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1909-19 [17620423.001]
  • [Cites] Neurosci Lett. 2007 Jun 21;421(1):37-41 [17548155.001]
  • [Cites] Cell Biol Int. 2007 Sep;31(9):1027-35 [17468017.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Brain Res. 2007 Mar 9;1136(1):190-9 [17239831.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1882-3 [16809515.001]
  • [Cites] Liver Int. 2005 Oct;25(5):1069-73 [16162168.001]
  • (PMID = 19688070.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2699093
  • [Keywords] NOTNLM ; Apoptosis / Astrocytoma / Fas / Ginsenoside / Reactive oxygen species
  •  go-up   go-down


99. Owen CM, Linskey ME: Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle. J Neurooncol; 2009 May;93(1):139-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 18 lesions involving the corpus callosum, 13 (72.2%) were GBM 2 were anaplastic astrocytoma, and 1 each were found to be anaplastic oligodendroglioma, primary central nervous system lymphoma (PCNSL) and tumescent MS.
  • Of 25 multifocal lesions, malignant primary brain tumor was diagnosed in 17 (68%) (11 GBM, 3 PCNSL, 2 anaplastic ologodendroglioma, and 1 anaplastic astrocytoma).

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comput Aided Surg. 1998;3(2):51-6 [9784952.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):11-5 [11932818.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):830-5; discussion 835-7 [11564243.001]
  • [Cites] Br J Neurosurg. 2006 Aug;20(4):222-6 [16954072.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):170-6; discussion 176-8 [8747966.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS146-56; discussion ONS146-56 [16888546.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1985;35:70-4 [3911747.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):368-72 [7850537.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12 (6):1165-75 [1763744.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):233-7 [16509497.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):31-5 [9647169.001]
  • [Cites] J Neurooncol. 2005 Jun;73(2):173-9 [15981109.001]
  • [Cites] Appl Neurophysiol. 1982;45(4-5):426-30 [7036878.001]
  • [Cites] Surg Neurol. 1984 Sep;22(3):222-30 [6379944.001]
  • [Cites] Surg Neurol. 1980 Oct;14(4):275-83 [7001660.001]
  • [Cites] J Neurosurg. 2005 May;102(5):897-901 [15926716.001]
  • [Cites] Neurosurg Rev. 1994;17 (1):59-66 [8078610.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):65-70 [16132501.001]
  • [Cites] J Clin Neurosci. 2004 Apr;11(3):263-7 [14975414.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):930-7 [3302751.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):907-12; discussion 912-4 [8905744.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):193-200 [11465400.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):110-8 [12046728.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):165-8 [8027795.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):358-62 [15949232.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):370-87 [12186466.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):682-94; discussion 694-5 [7808612.001]
  • [Cites] J Neurosurg. 2001 Apr;94(4):545-51 [11302651.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):160-8 [10413173.001]
  • [Cites] Neurosurgery. 1983 Mar;12 (3):277-85 [6341870.001]
  • [Cites] Surg Neurol. 2001 Dec;56(6):366-71; discussion 371-2 [11755966.001]
  • [Cites] Acta Neurochir (Wien). 1981;57(3-4):213-34 [6269368.001]
  • (PMID = 19430891.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


100. Bentsion DL, Gvozdev PB, Sakovich VP, Fialko NV, Kolotvinov VS, Baiankina SN: [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2006 Jan-Mar;(1):18-21; discussion 21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histostructural distribution was as follows: low-grade astrocytoma (grade II according to the WHO classification) in 2 patients, anaplastic astrocytoma (AA) in 3, glioblastoma multiforme (GBM) in 5.
  • Five patients had solid tumor deposits in the brain.
  • After having histological findings, plastic intrastats whose number had been determined by the volume of a target were implanted into a tumor by the predetermined path.
  • All patients with low-grade astrocytoma and one patient with anaplastic astrocytoma were alive at month 24 after treatment termination.
  • The mean lifespan of patients with malignant gliomas and solid tumor metastasis was 11.5 and 5.8 months, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739930.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down